Eye Research Foundation Inc

1. Allergan Inc. $4,714,552 190 payments
2. AbbVie, Inc. $3,985,920 142 payments
3. Bausch & Lomb Americas Inc. $630,780 4 payments
4. Novartis Pharmaceuticals Corporation $417,470 5 payments
5. Alcon Research LLC $282,265 8 payments
6. Oyster Point Pharma, Inc. $82,500 1 payment
7. Amneal Pharmaceuticals LLC $71,293 4 payments
8. Sun Pharmaceutical Industries Inc. $58,998 8 payments
9. Kala Pharmaceuticals, Inc. $39,060 5 payments

1. A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $1,278,847 18 payments
2. Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $1,032,279 12 payments
3. A Randomized, Multicenter, Double-Masked, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness $630,780 4 payments
4. A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) $619,167 9 payments
5. A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines $580,200 12 payments
6. Ph 3 Open-label Extension Study $527,290 12 payments
7. A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines $428,850 10 payments
8. Ph 3 Pivotal GL and GL+LCL - US/EU $330,556 13 payments
9. Ph 3 Pivotal LCL Only - US/EU $328,535 13 payments
10. Ph 3 Open-label Extension Study $324,435 12 payments

1. Other $58,998 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.